News | April 18, 2014

UC San Diego Bioengineer Develops New Biomaterial Therapy for Treating Heart Attacks

April 18, 2014 — A University of California, San Diego scientist has developed a new biomaterial that could potentially treat heart attacks. Karen Christman, Ph.D., associate professor of bioengineering at UC San Diego Jacobs School of Engineering, has been at work on a new injectable hydrogel, which is designed to repair damaged cardiac tissue following a heart attack.

The hydrogel has been licensed to San Diego-based startup Ventrix Inc., which is planning the first human clinical trials of the technology. Christman is a co-founder of Ventrix.

In a 2013 study published in Science Translational Medicine, Christman reported the semi-solid porous gel encourages cells to repopulate areas of damaged cardiac tissue and to preserve heart function. The hydrogel forms a scaffold to repair the tissue and increases cardiac muscle.

Christman was a faculty speaker at Research Expo, a UC San Diego Jacobs School of Engineering event, on April 17, where she presented the new technology.

For more information: http://www.jacobsschool.ucsd.edu/news/news_releases/release.sfe?id=1502

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init